Michigan Dermatology Institute | Waterford Township, MI

Research site

(Unclaimed)

Location

2665 Elizabeth Lake Rd, Waterford, Michigan, United States of America

Site insights

Top conditions

Top treatments

Ritlecitinib

Ruxolitinib

HZN-7734

EVO756

Amlitelimab

Ustekinumab

Orismilast

Camoteskimab

Upadacitinib

Daxdilimab

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

7 of 16 total trials

A Long-Term Study to Learn About The Study Medicine Called Ritlecitinib in Children With Severe Alopecia Areata. (B7981028)

The purpose of this clinical trial is to learn about long-term safety and long-term effects of the study medicine (called ritlecitinib) for the poten...

Enrolling

Severe Alopecia Areata

Drug: Ritlecitinib lower dose

Drug: Ritlecitinib higher dose

A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS)

Hidradenitis suppurativa (HS) is an inflammatory skin disease that causes painful lesions in the axilla (underarm), inguinal (groin) and anogenital (...

Enrolling

Hidradenitis Suppurativa

Drug: Upadacitinib

Drug: Placebo

A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)

The purpose of this study is to evaluate effect of povorcitinib on itch and skin lesions in participants with prurigo nodularis.

Active, not recruiting

Prurigo Nodularis

Drug: Placebo

Drug: Povorcitinib

A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo

The purpose of this study is to to evaluate the safety and efficacy of ruxolitinib cream in pediatric participants with nonsegmental vitiligo.

Enrolling

NonSegmental Vitiligo

Drug: Ruxolitinib Cream

Drug: Vehicle Cream

A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata (B7981027)

The purpose of this study is to learn about the safety and effects of the study medicine (called ritlecitinib) for the possible treatment of severe a...

Enrolling

Severe Alopecia Areata

Drug: Ritlecitinib higher dose

Drug: Placebo

Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis (ATLANTIS)

This is a single group, 1-arm, long-term safety study for treatment of participants with moderate to severe atopic dermatitis (AD).The purpose of thi...

Active, not recruiting

Dermatitis Atopic

Drug: Amlitelimab